Trump executive order on psychedelics research — what actually changed?

The January 2025 executive order directed federal agencies (primarily VA and DoD) to review evidence on psychedelic therapies for veteran PTSD and TBI, and to remove administrative barriers to veteran access to clinical trials. It did NOT reschedule psilocybin or MDMA. It did NOT fund treatment. It did NOT create any federal program. What it did is: directed agencies to produce a report within 90 days on the state of the evidence and regulatory barriers, and formally encouraged VA to expand clinical trial participation. The symbolic value is real (it signals federal interest) but the immediate practical impact is limited.

The important downstream effect: it is now politically easier for VA hospitals and DoD facilities to participate in psychedelic research and to refer veterans to clinical trials. Before, even clinicians who believed in the research were reluctant to recommend psychedelic trials to veteran patients given the political environment. The EO changes that political calculus even without changing any law.

What it doesn't do: doesn't help the majority of veterans who want access now and aren't near a clinical trial site. Heroic Hearts Project and similar nonprofits are still doing more tangible work for veteran access than the EO itself. The legislative pathway (VETS Act, etc.) is still what would actually create systemic access.